All In Biotech

Drug Trial Radar · NCT00410982

Gemcitabine Plus Busulfan, Melphalan and Hematopoietic Cell Transplant for Advanced Lymphoid Malignancies

Gemcitabine Combined With Busulfan and Melphalan, With Hematopoietic Cell Transplantation, for Patients With Poor-prognosis Advanced Lymphoid Malignancies

Last checked: Nov 20, 2026Latest source record: Jun 3, 2016 (this record)Source: ClinicalTrials.govMethods & limitations

Completed

Status

Completed

Enrollment

145

Actual

Start

Dec 2006

Primary completion

Sep 2012

Study completion Sep 2012

Sponsor

Lead sponsor
M.D. Anderson Cancer CenterAcademic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 13, 2006

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Not applicable (single group)
Model
Single group
Masking
None
Primary purpose
Treatment
Who can join
All sexes, from 18 years, up to 69 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical research study is to find the highest tolerated dose of gemcitabine that can be given with busulfan and melphalan. The safety of this drug combination will also be studied.

Conditions

  • Leukemia
  • Lymphoma
  • Myeloma

Interventions

  • BusulfanDrug

    Day -10 = 32 mg/m\^2 Intravenous Test Dose; Days -8 thru -5 = 105 mg/m\^2 Intravenous

  • GemcitabineDrug

    Day -8 = 75 mg/m\^2 Intravenous bolus; Day -3 = 75 mg/m\^2 Intravenous bolus.

  • MelphalanDrug

    Day -3 and Day -2 = 60 mg/m\^2 Intravenous.

  • Hematopoietic Cell TransplantationOther

    Infusion of stem cells on Day 0.

  • Rituximab for Patients with B-Cell MalignanciesDrug

    375 mg/m\^2 Intravenous on Days 1 and 8.

  • PaliferminDrug

    60 microgram/kg by vein on Days -13 to -11 and Days 0, +1, +2

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Maximum Tolerated Dose (MTD) of Gemcitabine with Busulfan + MelphalanTime frame: Baseline to Day 100 post transplant, up to 115 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • UT MD Anderson Cancer Center

    Houston, Texas

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.